Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1Phase 1 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Thoracic 1CNS 1

Conditions

Melanoma 40Colorectal Neoplasms 25Colonic Neoplasms 10Brain Neoplasms 8Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Rectal Neoplasms 5Skin Neoplasms 4Lung Neoplasms 3Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Digestive System Neoplasms 2Thyroid Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Solid Tumor 1Skin Diseases 1Recurrence 1Rectal Diseases 1Neurofibromatosis 1 1Multiple Myeloma 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Intestinal Neoplasms 1Intestinal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Neoplasm Metastasis × encorafenib × Clear all
NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Pfizer

Phase 1/2 Terminated
34 enrolled 44 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03898908 2025-05-21

EBRAIN-MEL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
48 enrolled 24 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT01436656 2024-10-28

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Pfizer

Phase 1 Completed
107 enrolled 49 charts
DermatologicGastrointestinal

Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Array BioPharma

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡